Area of Interest
Preclinical targeted therapy of esophageal squamous cell carcinoma (ESCC): We are particularly interested in developing targeted therapy of ESCC in vitro and in vivo with specific molecular alterations. These studies can be potentially translated into clinical studies. Current targets are (1) Nrf2 signaling pathway; (2) Sox2-âˆ†Np63 interaction.
Molecular mechanism and prevention of alcohol and tobacco-associated oro-esophageal cancer: The goal of this research direction is to understand how alcohol and tobacco carcinogens may cause oro-esophageal cancer, and how to prevent this type of cancer. Both pharmacological (pharmaceutical and dietary agents) and genetic approaches are employed to elucidate the mechanism of oro-esophageal carcinogenesis and design preventive strategies for clinical studies.
Positions and Honors
- Member, Lineberger Comprehensive Cancer Center & Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill, Chapel Hill, NC
- Associate Professor, Center for Gastrointestinal Biology & Disease & Center for Esophageal Disease & Swallowing, Division of Gastroenterology & Hepatology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC
- 2005 – Present Associate Professor, Cancer Research Program, Julius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, NC
- 2001 – 2005 Assistant Research Professor, Lab for Cancer Research, Rutgers University, Piscataway, NJ
- 2000 – 2001 Research associate, Lab for Cancer Research, Rutgers University, Piscataway, NJ
- 1991-1994 Resident orthopedic surgeon and research assistant, Arthritis Clinic & Research Center, People’s Hospital, Beijing Medical University, Beijing, P.R. China